A bipartisan
House of Representatives bill (H.R. 7667) introduced on May 6, 2022 aims to amend the Federal Food, Drug, and Cosmetic Act, as well as extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products. In section 524C, “Ensuring Cybersecurity of Devices,” the bill states, “For purposes of ensuring cybersecurity throughout the lifecycle [...]